Skip to main content

Table 2 Mutations identified by panel next-generation sequencing for cell lines (upper panel) and resistance models (lower panel) used in this study

From: CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab

Cell line Cell cycle control TP53 Cell death regulation RTK signaling PI3K-akt signaling MAPK-signaling Others
UT-SCC-23   DEL      SMAD4, FAT1
UM-SCC-11B   Cys110Ser      
UD-SCC-5   His47Tyr   ERBB4, PDGFR    FAT1, PCDH15
UD-SCC-4   DEL   KDR, MYC    FAT1, PCDH15
UM-SCC-22B   Tyr88Cys CASP8 KIT    NOTCH1, SMAD4, FAT1, PCDH15,
SCC-9   Val142fs   KDR, RET    FAT1, Notch1, PCDH15
UM-SCC-17B     EGFR, KDR, KIT PIK3CA HRAS SMAD4, FAT1
UM-SCC-74B     KDR, KRAS    CDH1, FAT1, NOTCH1, PCDH15
UT-SCC-15 CDKN2A Arg282Trp CASP8     CDH1, FAT1
UM-SCC-25 CDKN2A    ERBB4    SMAD4, FAT1
FaDu CDDP-S/R CDKN2A Arg248Leu 2% ➔ 47%      SMAD4
UD-SCC-4 CDDP-S/R   DEL   MYC, KDR 70% ➔ 100%    FAT1, PCDH15, NSD1 0% ➔ 38%
UT-SCC-9 CET-S/R CDKN2A DEL   MET 35% ➔ 50%    FAT1
UM-SCC-22B CET-S/R   Tyr88Cys CASP8 KIT    NOTCH1, SMAD4, FAT1, PCDH15
  1. Mutations which affect protein function, as predicted by the SIFT [41] and PolyPhen [42] program are presented in bold, percentages of allele frequency are given if they differed between parental and resistant cells.